Search
Patexia Research
Case number 2021-1071

Mylan Laboratories Ltd. v. Janssen Pharmaceutica, N.V. > Documents

Date Field Doc. No.Description (Pages)
Apr 23, 2021 0 MYLAN LABORATORIES LTD. v. JANSSEN PHARMACEUTICA, N.V. [ORDER] [precedential] (0)
Mar 12, 2021 32 PRECEDENTIAL ORDER filed. Janssen's motion [8] to dismiss is granted. Mylan's petition for a writ of mandamus is denied. Costs are awarded to Janssen. By: Motions Panel. Service as of this date by the Clerk of Court. [761791] [MJL] [Entered: 03/12/2021 09:23 AM] (0)
Feb 12, 2021 31 Submitted after ORAL ARGUMENT on Appellee's Motion to Dismiss to Panel: Newman, Circuit Judge; Moore, Circuit Judge and Stoll, Circuit Judge.Arguing counsel: Deepro Mukerjee for Mylan Laboratories Ltd., Mr. Pratik A. Shah for Janssen Pharmaceutica, N.V. and Melissa N. Patterson for Andrew Hirshfeld.Oral Argument Audio available here. [755787] [JCP] [Entered: 02/12/2021 12:03 PM] (0)
Feb 11, 2021 30 Official caption revised to reflect Andrew Hirshfeld as Performing the Functions and Duties of the Under Secretary of Commerce for Intellectual Property and Director of the USPTO. (see attached). Service as of this date by the Clerk of Court. [755563] [MJL] [Entered: 02/11/2021 04:21 PM] (0)
Feb 2, 2021 28 Entry of appearance for Melissa N. Patterson; Weili J. Shaw as counsel for Intervenor Andrei Iancu. Service: 02/02/2021 by email. [753373] [21-1071] [Melissa Patterson] [Entered: 02/02/2021 12:22 PM] (0)
Feb 2, 2021 29 Amended Response to notice of oral argument from Intervenor Andrei Iancu. Service: 02/02/2021 by email. [753374] [21-1071] [Melissa Patterson] [Entered: 02/02/2021 12:27 PM] (0)
Jan 29, 2021 27 ORDER filed. The parties and the United States should come to argument prepared to address the questions raised in this order (see attached). By: Per Curiam. Service as of this date by the Clerk of Court. [752881] [MJL] [Entered: 01/29/2021 05:13 PM] (0)
Jan 28, 2021 26 Docketing Statement for the Intervenor Andrei Iancu. Service: 01/28/2021 by email. [752305] [21-1071] [Michael Forman] [Entered: 01/28/2021 12:25 PM] (0)
Jan 21, 2021 25 Response to notice of oral argument from Appellant Mylan Laboratories Ltd.. Service: 01/21/2021 by email. [750657] [21-1071] [Deepro Mukerjee] [Entered: 01/21/2021 03:40 PM] (0)
Jan 21, 2021 24 Response to notice of oral argument from Appellee Janssen Pharmaceutica, N.V.. Service: 01/21/2021 by email. [750438] [21-1071] [Pratik Shah] [Entered: 01/21/2021 09:42 AM] (0)
Jan 21, 2021 23 Response to notice of oral argument from Intervenor Andrei Iancu. Service: 01/21/2021 by email. [750401] [21-1071] [Michael Forman] [Entered: 01/21/2021 08:28 AM] (0)
Jan 15, 2021 22 Clerk's letter to Appellant Mylan Laboratories Ltd., Appellee Janssen Pharmaceutica, N.V. and Intervenor Andrei Iancu regarding Telephonic Argument Orientation. Service as of this date by the Clerk of Court. [749810] [JAB] [Entered: 01/15/2021 02:28 PM] (0)
Jan 14, 2021 20 ORDER filed granting [12] the Director's motion to intervene. The revised official caption is reflected above. The Director is directed to file a docketing statement no later than 14 days from the date of filing of this order. Telephonic oral argument on the motion to dismiss is scheduled for Friday, February 12, 2021 at 10:00 a.m. Janssen, Mylan, and the Director will each be allotted fifteen minutes for argument. (Per Curiam). Service as of this date by the Clerk of Court. [749374] [LMS] [Entered: 01/14/2021 09:38 AM] (2)
Jan 14, 2021 21 NOTICE OF TELEPHONIC ORAL ARGUMENT. Panel: 2102N. Case scheduled February 12, 2021. Response to Notice of Oral Argument due: 01/21/2021. The Clerk's Office will provide additional instructions to counsel at least one week ahead of argument. Please review the attached Notice. The response to notice of oral argument form can be found here. The Oral Argument Guide can be found here. Service as of this date by the Clerk of Court. [749605] [MJL] [Entered: 01/14/2021 05:13 PM] (1)
Dec 21, 2020 19 REPLY of Appellee Janssen Pharmaceutica, N.V. to response [16]. Service: 12/21/2020 by email. [744389] [21-1071] [Pratik Shah] [Entered: 12/21/2020 03:15 PM] (12)
Dec 8, 2020 18 ORDER granting motion to extend time [17] filed by Appellee Janssen Pharmaceutica, N.V. Janssen's reply in support of its motion to dismiss is due no later than December 21, 2020. Service as of this date by the Clerk of Court. [741102] [LMS] [Entered: 12/08/2020 01:08 PM] (2)
Dec 7, 2020 14 RESPONSE from USPTO Director to the motion [8]. Service: 12/07/2020 by email. [740776] [21-1071] [Michael Forman] [Entered: 12/07/2020 03:21 PM] (26)
Dec 7, 2020 15 Entry of appearance for Johnjerica Hodge as counsel for Appellant Mylan Laboratories Ltd.. Service: 12/07/2020 by email. [740828] [21-1071] [Johnjerica Hodge] [Entered: 12/07/2020 04:54 PM] (3)
Dec 7, 2020 16 RESPONSE of Appellant Mylan Laboratories Ltd. to the motion [8]. Service: 12/07/2020 by email. [740923] [21-1071] [Eric Werlinger] [Entered: 12/07/2020 09:41 PM] (30)
Dec 7, 2020 17 MOTION of Appellee Janssen Pharmaceutica, N.V. to extend time. Service: 12/07/2020 by email. [740926] [21-1071] [Pratik Shah] [Entered: 12/07/2020 09:54 PM] (7)
Dec 3, 2020 12 Notice of Intervention pursuant to the provisions of 35 USC Section 143 from the Director of the United States Patent and Trademark Office. Service: 12/03/2020 by email. [739935] [21-1071] [Michael Forman] [Entered: 12/03/2020 11:37 AM] (3)
Dec 3, 2020 13 Entry of appearance for Michael S. Forman; Mary L. Kelly; Molly R. Silfen; Thomas W. Krause; Farheena Y. Rasheed as counsel for Intervenor, Director - U.S. Patent and Trademark Office. Service: 12/03/2020 by email. [739936] [21-1071] [Michael Forman] [Entered: 12/03/2020 11:40 AM] (2)
Nov 30, 2020 11 Notice from the United States Patent and Trademark Office of non-filing of the certified list. Service: 11/30/2020 by email. [738852] [EKD] [Entered: 11/30/2020 03:51 PM] (3)
Nov 13, 2020 10 ORDER granting motion to extend time to file [9]. Mylan's response to the motion to dismiss is due no later than December 7, 2020. Service as of this date by the Clerk of Court. [735452] [NL] [Entered: 11/13/2020 03:04 PM] (2)
Nov 9, 2020 9 MOTION of Appellant Mylan Laboratories Ltd. to extend time. Service: 11/09/2020 by email. [734587] [21-1071] [Eric Werlinger] [Entered: 11/09/2020 06:05 PM] (11)
Nov 5, 2020 8 MOTION of Appellee Janssen Pharmaceutica, N.V. to terminate appeal through dismissal. Cases to be terminated: 21-1071. (Briefing suspended pursuant to FCR 31 pending resolution of the motion).. Service: 11/05/2020 by email. [734058] [21-1071] [Pratik Shah] [Entered: 11/05/2020 07:36 PM] (40)
Nov 3, 2020 2 Entry of appearance for Pratik A. Shah; Z.W. Julius Chen; Ruben H. Munoz; Barbara L. Mullin; Andrew D. Cohen as counsel for Appellee Janssen Pharmaceutica, N.V.. Service: 11/03/2020 by email. [733432] [21-1071] [Pratik Shah] [Entered: 11/03/2020 05:15 PM] (2)
Nov 3, 2020 3 Certificate of Interest for Appellee Janssen Pharmaceutica, N.V.. Service: 11/03/2020 by email. [733433] [21-1071] [Pratik Shah] [Entered: 11/03/2020 05:16 PM] (3)
Nov 3, 2020 4 Docketing Statement for the Appellee Janssen Pharmaceutica, N.V.. Service: 11/03/2020 by email. [733434] [21-1071] [Pratik Shah] [Entered: 11/03/2020 05:17 PM] (2)
Nov 3, 2020 5 Docketing Statement for the Appellant Mylan Laboratories Ltd.. Service: 11/03/2020 by email. [733439] [21-1071] [Deepro Mukerjee] [Entered: 11/03/2020 06:00 PM] (3)
Nov 3, 2020 6 Entry of appearance for Deepro R. Mukerjee; Lance A. Soderstrom; Jitendra Malik; Eric Werlinger as counsel for Appellant Mylan Laboratories Ltd.. Service: 11/03/2020 by email. [733442] [21-1071] [Deepro Mukerjee] [Entered: 11/03/2020 06:03 PM] (3)
Nov 3, 2020 7 Certificate of Interest for Appellant Mylan Laboratories Ltd.. Service: 11/03/2020 by email. [733443] [21-1071] [Deepro Mukerjee] [Entered: 11/03/2020 06:04 PM] (4)
Oct 20, 2020 1 Appeal docketed. Received: 10/20/2020. [730178] Entry of Appearance is due on 11/03/2020. Certificate of Interest is due on 11/03/2020. Docketing Statement is due on 11/03/2020. Certified List is due on 11/30/2020. [EKD] [Entered: 10/20/2020 11:55 AM] (36)
Menu